ALKBH5介导NEIL2的m6A甲基化调控LECs氧化损伤在年龄相关性白内障发生中机制研究
批准号:
82101101
项目类别:
青年科学基金项目(C类)
资助金额:
30.0 万元
负责人:
康丽华
依托单位:
学科分类:
晶状体与白内障
结题年份:
2024
批准年份:
2021
项目状态:
已结题
项目参与者:
康丽华
中文摘要
氧化损伤是年龄相关性白内障(ARC)的重要发病机制。申请人以往研究表明表观遗传参与调控氧化损伤修复基因的功能和ARC的发生,而RNA甲基化(m6A)在ARC中的机制尚不清楚。前期预实验发现:ARC患者晶状体上皮细胞(LECs)中RNA去甲基酶ALKBH5高表达;碱基切除修复基因NEIL2的m6A修饰在ARC患者LECs中减少,提示可能是ALKBH5的潜在靶基因;NEIL2靶向结合并调控氧化损伤关键基因KEAP1。据此提出假说:ALKBH5通过m6A去甲基化下调NEIL2的表达,使得NEIL2与KEAP1相互作用下降,引起KEAP1表达升高导致LECs氧化损伤和ARC发病。本研究拟通过临床组织样本、细胞和小鼠模型,利用Crispr-Cas9、MeRIP-PCR、免疫共沉淀等方法,探讨ALKBH5介导NEIL2的m6A去甲基化靶向调控KEAP1在ARC发生中的机制,为ARC的防治提供新的思路。
英文摘要
Oxidative damage is a critical risk factor in the development of age-related cataract (ARC). Our previous projects have shown that epigenetics participate in the formation of ARC by regulating the functions of oxidative damage repair genes. However, the mechanism of RNA methylation, especially N6-methyladenine (m6A) modification in ARC formation is not clear.Our preliminary study found that m6A demethylase ALKBH5 was highly expressed in lens epithelial cells (LECs) of ARC patients, while the m6A methylation of NEIL2 was reduced, which suggesting that NEIL2 might be a potential target gene of ALKBH5.We also found that NEIL2 could interact with KEAP1 and regulate the expression of KEAP1, which known as an essential role in oxidative damage.On the basis of these, we speculate that m6A demethylase ALKBH5 might decrease the interaction between NEIL2 and KEAP1 by downregulating the expression of NEIL2, resulting in the increased expression of KEAP1, oxidative damage of LECs and ARC formation.For the purpose to explore the mechanism of ALKBH5-mediated m6A demethylation of NEIL2 for regulating KEAP1 in ARC formation, we used Crispr-cas9, MeRIP-PCR, co-immunoprecipitation and other methods from many aspects and levels such as tissue, cell, mouse model. In summary, we hope to provide new ideas for the prevention and treatment of ARC.
年龄相关性白内障是全球首位的致盲性眼病,其病因及发病机制仍不明确。本项目采用病例对照研究,选取90例ARC患者(皮质型、核型和后囊下型各30例)及30例年龄匹配的对照组。采用qRT-PCR和WB检测患者、小鼠LECs以及LECs氧化损伤模型中NEIL1/2的表达。通过MeRIP-seq评估患者LECs中NEIL1/2的m6A修饰程度。甲基化MeRIP-PCR检测干预m6A甲基化酶后LECs中NEIL1/2的m6A修饰程度。RNA免疫沉淀-聚合酶链反应RIP-PCR评估ARC患者LECs中与m6A识别酶相互作用的NEIL1/2的mRNA水平。qRT-PCR和WB检测干预m6A调节酶后的NEIL1/2的表达水平。免疫沉淀评估过表达NEIL1/2后KEAP1与NRF2的相互作用并采用WB检测过表达NEIL1/2后NRF2的蛋白质表达。然后在LECs氧化损伤模型中过表达NEIL1/2和使用NRF2抑制剂ML385处理,分别采用WB检测DNA损伤、凋亡和线粒体稳态相关蛋白的表达,应用Mito-Tracker荧光探针评估线粒体数量和形态,JC-1染色检测线粒体膜电位,mtSOX染色检测线粒体超氧化物水平。最后在体外大鼠晶状体氧化损伤模型中敲低NEIL1和使用NRF2激活剂ML334处理后观察晶状体混浊面积比例;3月龄的CFW-Em/J小鼠玻璃体内注射AAV2-NEIL1,2个月后,进行了裂隙灯和前段光学相干断层扫描检查。结果发现:ARC患者、CFW-Em/J小鼠LECs和LECs氧化损伤模型中NEIL1表达降低,NEIL1的m6A修饰程度增加,NEIL2的m6A修饰程度降低。METTL14上调NEIL1的m6A修饰水平,ALKBH5下调NEIL2的m6A修饰水平。YTHDF2以METLL14/m6A依赖的方式负调控NEIL1表达。NEIL1/2抑制KEAP1与NRF2相互作用并激活NRF2表达。氧化应激下,NEIL1降低LECs中DNA氧化损伤和凋亡程度并通过提高TFAM和PGC1-α蛋白质水平和MMP,抑制DRP1和FIS1蛋白质水平和Mito-SOX水平,促进线粒体稳态,该效应被NRF2抑制剂ML385逆转。氧化应激下,NRF2激活剂ML334可显著逆转因NEIL1缺乏加重的晶状体混浊,可作为ARC防治的新靶点。已发表SCI论文9篇,中文文章4篇,参加国家级会议11次。
国内基金
海外基金